NIH launches antithrombotics trials in COVID-19 patients
The adaptive Phase III trials will assess whether various types and doses of blood thinners can prevent COVID-19 patients forming potentially fatal blood clots.
List view / Grid view
News
Promising interim results from ALS study testing IPL344
The data suggests disease deterioration was halved in the six Amyotrophic Lateral Sclerosis (ALS) patients treated with IPL344 over eight months.
Phase I trial finds potential COVID-19 antibody treatment safe in healthy volunteers
A first-in-human Phase I clinical trial of potential COVID-19 antibody CT-P59 has shown the treatment is well tolerated in healthy subjects.
British pharma responds to free trade agreement between UK and Japan
The ABPI has said that the new UK-Japan free trade agreement will benefit the pharma industry, providing continuity for life science businesses.
Clinical trial for AstraZeneca Oxford COVID-19 vaccine candidate to resume
After the clinical trial for AZD1222 was halted last week, the studies for AstraZeneca's COVID-19 vaccine candidate will now resume.
Few CMOs equipped to manufacture cell and gene therapies, finds study
A report has said that with only 152 CMOs able to manufacture the 7,000 cell and gene therapies in the pipeline, production bottlenecks may occur.
Impact of COVID-19 on clinical trials continuing, say researchers
An analysis of the impact of COVID-19 on clinical trials has shown this is increasing, with many sites unable to fully resume practice.
Imfinzi approved in EU to treat extensive-stage small cell lung cancer
Imfinzi (durvalumab) has been approved by the European Commission as a first-line treatment for extensive-stage small cell lung cancer, with chemotherapy.
Russia to supply Mexico with 32 million doses of Sputnik V
The Russian Direct Investment Fund (RDIF) said the supply of the COVID-19 vaccine should enable 25 percent of the population to be vaccinated.
$65 million expansion to HPAPI manufacturing facility
The expansion will be specifically designed to manufacture high-potency active pharmaceutical ingredients (HPAPIs) and complex antibody-drug conjugates (ADCs).
Pfizer and BioNTech may supply EU with 200 million doses of COVID-19 vaccine
The companies and European Commission will soon enter contract negotiations for the supply of their investigational COVID-19 vaccine candidate BNT162b2.
COVID-19 vaccine tablet induces systemic and mucosal immune responses
The researchers suggest inducing a mucosal immune response may be crucial to protect against SARS-CoV-2 infection and that the tablet formulation could overcome several major challenges associated with injectable vaccines.
Biopharma pledges to uphold scientific integrity in COVID-19 vaccine development
Nine biopharma CEOs pledged to make the integrity of the scientific process and sufficient supply priorities in the development of COVID-19 vaccines.
Dexamethasone Taw application to treat COVID-19 to be evaluated by EMA
Dexamethasone Taw will be examined by the EMA on an accelerated assessment timetable, to assess whether it should be given to patients with COVID-19.
British pharma industry responds to new Brexit guidance from MHRA
The ABPI has responded to new guidance, intended to prepare pharma companies for the end of the Brexit transition period, from the MHRA.
